裕興科技(08005.HK):智能生活新產品完成初步開發
裕興科技(08005.HK)表示,通過自身於人工智能之研發能力,於開發應用於智能生活新產品的技術上已取得階段性成果,新產品樣品之初步開發已完成,並正於調試階段中,包括「虛擬數字人」及非同質化代幣(NFT)區塊鏈技術在內的多項創新技術發明正申請發明專利,融合3D虛擬實境及人工智能語音之技術,將爲客戶於不同的定製場景提供綜合智能生活及辦公解決方案。
公司認爲,新產品線的推出將有助於保持市場競爭優勢並捕捉市場先機,將具備潛力以提升盈利能力及股東的價值,新技術及產品之估值初步估計超過1.5億美元,預計將獲得超過2,000萬美元於其首輪融資,用於技術創新及產品開發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.